It more commonly develops in cases showing previous positivity of antithyroid antibodies and a family history of autoimmune thyroid disease [2] and in patients treated with programmed death 1 (PD1) inhibitors than cytotoxic T-lymphocyte-associated protein 4 inhibitors [3]. This evidence concerns the gene CTLA4 and autoimmune thyroid disease.